N-linked glycosylation plays a crucial role in the secretion of HMGB1 by 怨쎈쭔�꽠 & �떊�쟾�닔
RESEARCH ARTICLE
N-linked glycosylation plays a crucial role in the secretion of
HMGB1
Young Hun Kim1,2,*, Man Sup Kwak1,*, Jun Bae Park3, Shin-Ae Lee1, Ji Eun Choi4, Hyun-Soo Cho3,‡ and
Jeon-Soo Shin1,2,5,‡
ABSTRACT
HMGB1 protein is a delayed mediator of sepsis that is secreted to
the extracellular milieu in response to various stimulants, inducing a
pro-inflammatory response. HMGB1 is devoid of an endoplasmic
reticulum (ER)-targeting signal peptide; hence, the mechanism of
extracellular secretion is not completely understood, although
HMGB1 is secreted after being subjected to post-translational
modifications. Here, we identified the role of N-glycosylation of
HMGB1 in extracellular secretion. We found two consensus (N37 and
N134) and one non-consensus (N135) residues that were N-
glycosylated in HMGB1 by performing liquid chromatography
tandem mass spectrometry (LC-MS/MS) and analyzing for N-
glycan composition and structure. Inhibition of N-glycosylation with
tunicamycin resulted in a molecular shift of HMGB1 as assessed by
gel electrophoresis. Non-glycosylated double mutant (N→Q) HMGB1
proteins (HMGB1N37Q/N134Q and HMGB1N37Q/N135Q) showed
localization to the nuclei, strong binding to DNA, weak binding to
the nuclear export protein CRM1 and rapid degradation by
ubiquitylation. These mutant proteins had reduced secretion
even after acetylation, phosphorylation, oxidation and exposure to
pro-inflammatory stimuli. Taken together, we propose that HMGB1 is
N-glycosylated, and that this is important for its DNA interaction and is
a prerequisite for its nucleocytoplasmic transport and extracellular
secretion.
KEY WORDS: HMGB1, N-glycosylation, Post-translational
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INTRODUCTION
High mobility group box 1 (HMGB1) is a damage-associated
molecular pattern (DAMP) molecule located in the nucleus.
HMGB1 is secreted from activated monocytes and macrophages
after post-translational modification (PTM) (Bonaldi et al., 2003;
Youn and Shin, 2006), activation of an inflammasome pathway
mediated by double-stranded RNA-dependent protein kinase (PKR,
also known as EIF2AK2) (Lu et al., 2012), and through a pyruvate
kinase M2 (PKM)-mediated pathway (Yang et al., 2014). HMGB1
is secreted through a non-classical vesicle-mediated secretory
pathway (Gardella et al., 2002; Dupont et al., 2011). Additionally,
HMGB1 can be released from dying cells as a result of autophagy
(Thorburn et al., 2009), apoptosis (Bell et al., 2006), pyroptosis
(Nyström et al., 2013) and necroptosis (programmed necrosis)
mechanisms (Zou et al., 2013). HMGB1 can also initiate
inflammation (Scaffidi et al., 2002), and it has a role as a late
mediator of sepsis in both animal models and human patients
(Ombrellino et al., 1999; Wang et al., 1999; Sundén-Cullberg et al.,
2005). Extracellular HMGB1 binds to toll-like receptor (TLR) 2 and
4, as well as the receptor for advanced glycation end products
(RAGE), and activates NF-κB and extracellular-signal-regulated
protein kinases 1 and 2 (ERK1/2, also known as MAPK3 and
MAPK1, respectively) (Salmivirta et al., 1992; Hori et al., 1995;
Park et al., 2004) during sterile inflammation (Yang et al., 2010,
2015). HMGB1 interacts with host molecules of interleukin (IL)-1β
(Sha et al., 2008), chemokine (C-X-C motif ) ligand 12 (CXCL12)
(Schiraldi et al., 2012) and nucleosomes (Tian et al., 2007), as well
as with pathogen-associated molecular pattern (PAMP) molecules
of lipopolysaccharide (LPS) and lipoteichoic acid (LTA), which are
finally transferred to TLR4 and TLR2 receptors, respectively (Youn
et al., 2008; Kwak et al., 2015), and augment or modify pro-
inflammatory reactions. Intracellular HMGB1 is primarily located
in the nucleus, where it functions as a nucleosome stabilizer and a
regulator of transcription (Einck and Bustin, 1985; Lotze and
Tracey, 2005), and also as a chaperone-like molecule that inhibits
aggregation of polyglutamine (Min et al., 2013). In addition,
HMGB1 binds to beclin-1 and regulates induction of autophagy
(Tang et al., 2010).
Approximately 30 years ago, HMGB1 was reported to undergo
extensive PTMs, including acetylation (Sterner et al., 1979; Dimov
et al., 1990), phosphorylation (Sun et al., 1980; Kimura et al., 1985),
methylation (Boffa et al., 1979) and adenosine diphosphate (ADP)-
ribosylation (Tanuma et al., 1985). More recently, the molecular
aspects of HMGB1 PTMs [acetylation (Bonaldi et al., 2003),
phosphorylation (Youn and Shin, 2006), methylation (Ito et al.,
2007), and cysteine oxidation (Hoppe et al., 2006)] have been
investigated to determine the regulation of intracellular localization
and extracellular secretion of HMGB1 owing to its role as an
inflammatory mediator. The shuttling of HMGB1 between the
nucleus and the cytoplasm is tightly regulated; the nuclear importin
protein karyopherin-α1 and the nuclear exportin chromosomal
maintenance 1 (CRM1, also known as XPO1) are involved in
nucleocytoplasmic shuttling, which is influenced by modifications
of HMGB1 (Bonaldi et al., 2003; Youn and Shin, 2006). HMGB1
has no signal peptide targeting it to the endoplasmic reticulum (ER),
but a low degree of glycosyl modification has been identified in
HMGB1 in calf thymus (Reeves and Chang, 1983; Elton and
Reeves, 1986). The glycosylation residue and its role, however,
have not been identified at a molecular level, although glycosylation
is an important PTM.Received 25 June 2015; Accepted 9 November 2015
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HMGB1 has two N-glycosylation acceptor sites with a consensus
motif of NxS/T (x can be any amino acid other than proline) (Welply
et al., 1983 Marshall, 1974; Gavel and von Heijne, 1990). Here, we
demonstrated that HMGB1 can be N-glycosylated at the consensus
motifs at N37 and N134, and at a non-consensus motif at N135, by
using liquid chromatography tandem mass spectrometry (LC-MS/
MS) and gel shift analysis of the double mutant HMGB1N37Q/N134Q.
De-glycosylation of HMGB1 increases its binding to DNA and
decreases its binding to CRM1, as demonstrated through gel shift
and fluorescence recovery after photobleaching (FRAP) assays. We
found that de-glycosylated HMGB1 localized to the nucleus and
showed little extracellular secretion even when it had other PTMs.
These results demonstrate, at a molecular level, that HMGB1 can be
glycosylated at three asparagine residues, and that this modification
is an important prerequisite for cytoplasmic transport and
extracellular secretion resulting from pro-inflammatory stimuli.
RESULTS
HMGB1 is N-glycosylated
The PTMs of HMGB1 are important for HMGB1 nucleocytoplasmic
shuttling, extracellular secretion and transcriptional regulation.
However, HMGB1 glycosylation and the functional role of this
glycosylation have not been well characterized. The motif for N-
linked glycosylation is NxS/T and there are four asparagine residues
in HMGB1. Twomotifs located at N37 and N134, in the HMGB1A
and B box, respectively, are part of this NxS/T motif. These motifs
are conserved in rhesus macaques, cattle, rats, mice and chickens
according to an N-linked glycosylation prediction program
(NetNglyc, http://www.cbs.dtu.dk/services/NetNGlyc/) (Fig. 1A).
Wild-type human HMGB1 (HMGB1WT) does not contain an ER-
targeting signal peptide to allow for glycosylation. Therefore, to
observe HMGB1 glycosylation, which has been previously reported
(Reeves, 1981), we subcloned HMGB1WT DNA into a pFastBac
HT-B plasmid and produced HMGB1 protein in insect SF9 cells
(insHMGB1WT) for de-glycosylation analysis. HMGB1sig-pep,
which has an artificially added signal peptide and was produced
in HEK293F cells, was used as a positive control for N-glycosylated
HMGB1. Both insHMGB1WT and HMGB1sig-pep were treated with
PNGase F, a glycosidase enzyme that hydrolyzes N-linked
oligosaccharides, and then a migration shift analysis was
performed. We found that insHMGB1WT was shifted down after
enzyme treatment, similar to HMGB1sig-pep, suggesting that
HMGB1WT is glycosylated (Fig. 1B). Next, we treated CHO-K1,
HeLa and RAW264.7 cells with tunicamycin, an inhibitor of N-
linked glycosylation, for 24 h and observed the migration shift of
endogenous HMGB1 by western blotting. A band shift of
endogenous HMGB1 was observed after tunicamycin treatment
(Fig. 1C). Taken together, these data suggest that HMGB1 can be
N-glycosylated, confirming a previous report (Reeves, 1981).
When RAW264.7 cells were treated with brefeldin A and
nocodazole, inhibitors of protein transport from the ER to
the Golgi and of microtubule polymerization for vesicular
transport, respectively, LPS-stimulated HMGB1 secretion did
not decrease (Fig. 1D). These results suggest that the
Fig. 1. HMGB1 is N-glycosylated. (A) Four asparagine residues are present in human HMGB1. HMGB1 amino acid sequences of six species, humans, rhesus
monkeys, cows, rats, mice and chickens, were compared. Possible N-glycosylation residues were predicted using NetNglyc [NxS/T, http://www.cbs.dtu.dk/
services/NetNGlyc/] at N37, N134 and N135, which are boxed. (B) HMGB1sig-pep and insHMGB1WT were treated with PNGase F overnight at 37°C and
immunoblotted with anti-HMGB1 antibody. HMGB1sig-pep was produced in HEK293F cells, which were transfected with a plasmid containing an HMGB1 with an
artificially added signal peptide for ER-targeting in SF9 cells. insHMGB1WT protein was produced in insect SF9 cells transfected with a plasmid containing wild-
type HMGB1 without a signal peptide. Ig: immunoglobulin, a positive control glycoprotein. (C) CHO-K1, HeLa and RAW264.7 cells were treated with tunicamycin
for 24 h and the migration shift of endogenous HMGB1 was observed by western blotting. (D) RAW264.7 cells were treated with 1 µg/ml LPS for 24 h in the
presence or absence of 10 µg/ml of brefeldin A (BFA) and 10 µM nocodazole (Noco), inhibitors of protein transport from the ER to the Golgi and of microtubule
polymerization for vesicular transport, respectively, to observewhether HMGB1 was secreted by the conventional secretion pathway. Culture supernatants (Sup)
and whole-cell lysates (WCL) were harvested and HMGB1 was immunoblotted (IB) to assess whether it was secreted. Con, medium treated.
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conventional ER-Golgi secretion pathway is not related to HMGB1
secretion.
LC-MS/MS analysis of HMGB1
Next, we performed LC-MS/MS analysis of insHMGB1WT.
Treatment with PNGase F results in an increase in molecular
mass of 0.98 Da over the reference size of HMGB1 peptide
fragments. This change is due to the conversion of an asparagine
into an aspartic acid residue after a sugar molecule is deleted from
the amine group of asparagine by PNGase F (Hao et al., 2010),
confirming N-glycosylation in the site. HMGB1was glycosylated at
the N37 and N134 N-glycosylation consensus motifs. Interestingly,
N135 is not a typical residue for N-glycosylation, but received a
high score of glycosylation, and also displayed the molecular mass
change associated with N-glycosylation (Fig. S1A). Next, we
compared the molecular shift of insHMGB1WT and
insHMGB1N37Q/N134Q by performing western blotting and found
that insHMGB1N37Q/N134Q was shifted down compared to
insHMGB1WT, suggesting N-glycosylation of HMGB1 (Fig. S1B).
We repeated the LC-MS/MS analysis using purified Myc-tagged
HMGB1, which was transiently overexpressed in HEK293T cells
(Fig. 2A). Approximately 60% of the HMGB1 amino acid sequence
was successfully detected and sequenced (Fig. S2A). A peptide
including N37 differed between b6 (607.284) and b7 (722.310), and
a peptide including N134 and N135 differed between b6 (761.365)
and b7 (876.392), and between b7 (875.408) and b8 (990.435),
respectively (Fig. 2B; Fig. S2B). We next prepared naturally
expressed endogenous HMGB1, and repeated the LC-MS/MS
analysis to prove that HMGB1 glycosylation was not limited to the
artificial system. We purified endogenous HMGB1 protein from
cultured HEK293T cells, using the immunoprecipitation method.
The glycan modifications were identified at N37, N134 and N135
residues (Fig. S3). These data show that HMGB1 is N-glycosylated
at N37, N134 and N135 as determined by LC-MS/MS analysis.
Analysis of N-linked glycans from HMGB1
We next performed an LC-MS/MS analysis of the glycan structures
of HMGB1. Myc–HMGB1 was purified from HEK293T cells
transfected with myc–HMGB1 plasmid. A total ion chromatogram
of Rapifluor-labeled glycans from 15 µg HMGB1 released by
PNGase F was separated using an amide HILIC column. An
analysis of glycan profiling of human Ig was used as a test control
(data not shown). The chromatogram of the glycans eluted for
22 min was analyzed, where glycan composition and the proposed
structures of glycans can be suggested according to the elution time
(Fig. 3).
HMGB1 N-glycosylation is crucial for nucleocytoplasmic
translocation and secretion of HMGB1
Next, we tested the functional role of HMGB1 N-glycosylation.
HMGB1 is translocated to the cytoplasm when modified
by acetylation, phosphorylation or oxidation. Therefore, we
prepared expression plasmids for EGFP-tagged HMGB1WT,
HMGB1N37Q/N134Q and HMGB1N37Q/N135Q, and transiently
overexpressed these proteins in HEK293T cells to observe their
translocation and extracellular secretion. All HMGB1WTwas located
in the nuclei in the resting state and over 80%was translocated to the
cytoplasm upon treatment with trichostatin A (TSA; to induce
acetylation), phorbol 12-myristate 13-acetate (PMA; to induce
phosphorylation) or H2O2 (to induce oxidation) (Fig. 4A),
Fig. 2. LC-MS/MS analysis of HMGB1 N-glycosylation. (A) HEK293T cells transiently overexpressing Myc-tagged HMGB1WT were immunoprecipitated with
anti-Myc antibody for Coomassie Blue staining. PurifiedMyc-tagged HMGB1 (box) was extracted for analysis. M, marker. (B) LC-MS/MS analysis of purified Myc-
tagged HMGB1, which was transiently overexpressed in HEK293T cells. A peptide including N37 differed between b6 and b7, and N134 and N135 differed
between b6 and b7, and between b7 and b8, respectively.
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confirming previous results (Bonaldi et al., 2003; Hoppe et al., 2006;
Youn and Shin, 2006). However, the cytoplasmic translocation of
EGFP–HMGB1N37Q/N134Q and EGFP–HMGB1N37Q/N135Q was
severely decreased, to 20% and 40%, respectively, even after
treatment with TSA, PMA or H2O2 (Fig. 4B–D).
We next observed the extracellular secretion of HMGB1
(Fig. 4E). When HEK293T cells were transfected with EGFP–
HMGB1WT plasmid, EGFP–HMGB1WT secretion was profoundly
increased upon treatment with PMA, TSA and H2O2. However,
when transfected with the double mutants HMGB1N37Q/N134Q
and HMGB1N37Q/N135Q, their secretion was barely detectable even
after treatment with TSA, PMA or H2O2. When the cells were
transfected with single mutants HMGB1N37Q, HMGB1N134Q or
HMGB1N135Q, HMGB1 secretion was partially decreased after
stimulation. When we treated J774A.1 cells with LPS for 24 h or
starved the cells (Fig. 4F), the secretion patterns of HMGB1WT
and mutant proteins were similar. These data suggest that HMGB1
N-glycosylation at N37, N134 and N135 is a prerequisite for
nucleocytoplasmic translocation and secretion of HMGB1.
HMGB1 has improved mobility in the nucleus and improved
nuclear export upon N-glycosylation
HMGB1 is located in the nucleus under resting conditions and
binds to the minor groove of DNA; this binding ability is reduced
by methylation (Ito et al., 2007). We next tested whether
N-glycosylation of HMGB1 influences its movement in the nuclei
of live HEK293T cells by using FRAP analysis. FRAP data indicate
the rate at which fluorescent molecules exchange with
photobleached molecules. The recovery percentage of
fluorescence in the area of photobleaching will decrease if the
protein mobility is decreased. The recovery percentages of EGFP-
tagged HMGB1N37Q/N134Q and HMGB1N37Q/N135Q were lower
than that of EGFP–HMGB1WT within 4 s, suggesting slower
mobility (Fig. 5A). Therefore, we hypothesized that HMGB1
N-glycosylation influences its DNA binding. In order to test this,
plasmid DNA was incubated with insHMGB1WT and
insHMGB1N37Q/N134Q, and complex formation was observed.
As shown in Fig. 5B, the migration of complexes of
insHMGB1N37Q/N134Q and plasmid DNA were retarded compared
Fig. 3. Profiling of N-linked glycans from HMGB1. Myc–HMGB1 was purified from HEK293T cells transfected with Myc–HMGB1 plasmid. A total ion
chromatogram of Rapifluor-labeled glycans from 15 µg HMGB1 released by PNGase F was separated by an amide HILIC column. Structural assignments are
based onmonosaccharide composition and fragmentation analyses. The sugar symbols are those following theConsortium for Functional Glycomics (http://www.
functionalglycomics.org).
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to those of insHMGB1WT, and some complexes did not migrate and
remained in the wells. The effect of HMGB1 N-glycosylation on
binding between the N-acetyl-D-glucosamine (GlcNAc)-tagged
HMGB1 A or B box and double-stranded DNA (dsDNA) was
modeled using the structures of the complexes of HMGB1 A box
and B box bound to dsDNA as templates (PDB ID 1CKT and
2GZK, respectively) (Stott et al., 2006; Watson et al., 2007). As
shown in Fig. 5C, HMGB1 GlcNAc molecules at N37 and N134
induce steric hindrance on binding between HMGB1 and dsDNA.
Although the carbohydrate chains are flexible, they could
interfere with the phosphate backbone or the nucleic acids of the
dsDNA. As seen in Fig. 5C, only two GlcNAc molecules linked by
a glycosidic bond were drawn instead of entire carbohydrate chains
for clarity.
N-glycosylated HMGB1 has improved binding to CRM1
compared to non-glycosylated HMGB1
Nuclear HMGB1 is translocated to the cytoplasm after binding to the
nuclear exportin CRM1 (Bonaldi et al., 2003); hence, we tested the
binding of each mutant HMGB1 protein to CRM1. HEK293T cells
were co-transfected with CRM1 plasmid and either Myc-tagged
HMGB1WT, HMGB1N37Q/N134Q or HMGB1N37Q/N135Q for 48 h,
and then treated with 10 ng/ml TSA for 4 h to observe the effect of
HMGB1 acetylation. The cells were lysed and immunoprecipitated
with anti-Myc antibody and then immunoblotted with CRM1. As
shown in Fig. 6, myc–HMGB1WT binding to CRM1 increased after
TSA treatment, as previously described (Bonaldi et al., 2003).
HMGB1N37Q/N134Q and HMGB1N37Q/N135Q binding to CRM1 were
profoundly decreased when compared with HMGB1WT. These
results suggest that HMGB1 N-glycosylation is important for
binding to CRM1 and, thus, also for HMGB1 secretion.
Protein stability of de-glycosylated HMGB1 mutant proteins
Protein glycosylation is important in protein structure and stability.
Therefore, we tested the effect of glycosylation on the intracellular
stability of HMGB1 using HMGB1N37Q/N134Q and
HMGB1N37Q/N135Q plasmids. HEK293T cells were transfected
with HMGB1WT, HMGB1N37Q/N134Q or HMGB1N37Q/N135Q
plasmids and then treated with cycloheximide (CHX) to inhibit
protein translation and observe protein stability. Cells were
harvested and HMGB1 protein levels were analyzed by western
blotting. HMGB1WT protein levels were fairly consistent and
decreased by only 10% after 48 h. However, HMGB1N37Q/N134Q
and HMGB1N37Q/N135Q levels decreased by 60% and 30%,
respectively, after 48 h (Fig. 7A). These data suggest that
HMGB1 is degraded quickly when not properly glycosylated.
HEK293T cells were then transfected with HMGB1WT or
HMGB1N37Q/N134Q plasmids for 24 h and treated with a
proteasome inhibitor, MG132, in the presence or absence of
20 mM NH4Cl, a lysosomal inhibitor that prevents protease
activity. No significant change was observed in HMGB1WT
protein levels, but a dramatic recovery of HMGB1N37Q/N134Q was
Fig. 4. Effect of HMGB1 N-glycosylation on intracellular movement and secretion of HMGB1. (A–C) Movements of EGFP–tagged HMGB1WT, mutant
HMGB1N37Q/N134Q and HMGB1N37Q/N135Q in HEK293T cells. HEK293T cells were transfected with each plasmid for 48 h and then treated with 10 ng/ml TSA for
2 h, 250 nM PMA for 4 h or 50 μMH2O2 for 2 h. The movements of EGFP–HMGB1 were observed under a confocal microscope. (D) The localization of HMGB1-
EGFP (+) was recorded in 80 cells from the experiments described in A–C to determine the localization of HMGB1. Results are mean±s.e.m. *P<0.01, **P<0.001
compared to HMGB1WT (Student’s t-test). (E) HEK293T cells were transfected with the indicated EGFP-tagged HMGB1 plasmids for 24 h and then treated with
PMA, TSA or H2O2 for 18 h. Culture supernatants were harvested and immunoblotted (IB) to detect HMGB1. (F) J774A.1 cells were transfected with Myc-tagged
EGFP-HMGB1 plasmids for 24 h and then treated with 100 ng/ml LPS for 24 h. For starvation, cells were cultured in EBSS for 4 h. Culture supernatants were
collected and immunoblotted with anti-HMGB1 or anti-Myc antibodies to observe HMGB1 secretion. Nu, nucleus; Cyt, cytoplasm; Sup, supernatant.
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observed upon treatment with MG132 (Fig. 7B), suggesting that
HMGB1N37Q/N134Q is degraded in a proteasome-mediated pathway.
In addition, HMGB1N37Q/N134Q and HMGB1N37Q/N135Q were
ubiquitylated at K48, which is a degradation signal (Fig. 7C).
These results suggest that HMGB1 glycosylation is important for
HMGB1 stability.
DISCUSSION
HMGB1 secretion is modulated by the PTMs of acetylation,
phosphorylation, methylation and oxidation, which drive
HMGB1 to the cytoplasm and then to the extracellular space
through an unconventional secretion pathway. Although it has no
signal peptide, a low degree of glycosylation of HMGB1 has
been reported previously (Reeves and Chang, 1983; Elton and
Reeves, 1986; Chao et al., 1994), but the significance of
glycosylation and the glycosylation residue had not been
identified.
In this study, we demonstrated that HMGB1 could be
glycosylated by performing a gel shift analysis after PNGaseF
treatment and a tunicamycin-mediated N-glycosylation inhibition
assay. LC-MS/MS analysis showed that there were two N-
glycosylations at N37 and N134, at NxS/T consensus motifs, and
one at the non-classical consensus residue N135, in recombinant
HMGB1 proteins produced in both HEK293T and insect cells.
Recently, the sequence requirements of the acceptor substrate for N-
glycosylation have become less strict and it has been shown that
atypical (non-consensus) N-linked glycosylation is possible
(Valliere-Douglass et al., 2010; Schwarz and Aebi, 2011).
Previously, it had been reported that HMGB1 contains a low
degree of glycosyl modification in calf thymus (Reeves et al., 1981;
Reeves and Chang, 1983; Elton and Reeves, 1986; Chao et al.,
1994), and our data confirmed this glycosylation and identified the
glycosylation residues. In addition, recombinant HMGB1 expressed
in CHO cells treated with glycopeptidase F resulted in the removal
of an N-linked oligosaccharide (Li et al., 2004), and the HMG
family proteins HMGN1 and HMGN2 are also N-glycosylated
(Reeves and Chang, 1983). Taken together, these results suggest
that HMGB1 is N-glycosylated.
Fig. 5. DNA-binding ability of N-
glycosylated HMGB1. (A) FRAP analysis of
HMGB1WT, HMGB1N37Q/N134Q and
HMGB1N37Q/N135Q. HEK293T cells were
transfected with EGFP-tagged HMGB1
plasmids for 48 h, followed by photobleaching
of the nucleus and measurement of the
percentage recovery of fluorescence to
determine protein mobility. The experiment
was repeated four times, and the mean values
are shown. (B) DNA binding of HMGB1WT and
HMGB1N37Q/N134Q. HMGB1WT and
HMGB1N37Q/N134Q proteins were incubated
with plasmid DNA for 2 h at 37°C and DNA
migration was analyzed on a 1% agarose gel.
BSA, negative control protein. The arrowhead
indicates non-migrating plasmid-DNA–HMGB1
protein complexes in the wells. Data represent
one of two or four similar independent
experiments in A and B, respectively. (C) A
modeling study between GlcNAc-tagged
HMGB1 A and B boxes at N37 and N134,
respectively, and dsDNA as templates using
the WinCoot program. Illustration represents
the HMGB1 A or B box (green) and dsDNA
(cyan) complex structure. Two GlcNAc
molecules are shown as yellow stick models.
The cartoon or stick structures were produced
by the PyMOL program (http://www.pymol.org).
Fig. 6. Effect of HMGB1 N-glycosylation on CRM1 binding. HEK293T cells
were co-transfected with Myc-tagged HMGB1WT, HMGB1N37Q/N134Q (37/134)
or HMGB1N37Q/N135Q (37/135), and CRM1 plasmids for 48 h, and then treated
with 10 ng/ml TSA for 4 h. Cell lysates were immunoprecipitated (IP) with anti-
Myc antibody and then immunoblotted (IB) with anti-CRM1 antibody. The
relative density was than calculated. Data represent one of three similar
independent experiments.
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The significance of HMGB1 glycosylation was not known, even
though HMGB1 glycosylation was reported over 20 years ago.
Here, we show that HMGB1 N-glycosylation is required for
nucleocytoplasmic translocation and extracellular secretion.
When HEK293T cells transfected with HMGB1N37Q/N134Q or
HMGB1N37Q/N135Q plasmid were treated with PMA, TSA or H2O2,
the mutant HMGB1 primarily showed nuclear localization
with a profound reduction in extracellular secretion. These
results demonstrate that the PTMs of acetylation, phosphorylation
and oxidation are not sufficient for HMGB1 secretion, and
glycosylation is a prerequisite for HMGB1 translocation.
Based on the results showing that HMGB1N37Q/N134Q and
HMGB1N37Q/N135Q had stronger binding to nuclear DNA and
weaker binding to CRM1 compared to HMGB1WT, we suggest that
HMGB1 N-glycosylation at N37, N134 and N135 is important for
HMGB1 intracellular trafficking and secretion.
N-glycans are synthesized and transferred to polypeptides
containing a signal peptide, by glycosyltransferase, at aspargine
residues within the NxS/T sequon on the luminal side of the ER
and Golgi (Molinari, 2007; Hebert et al., 2014). However, the
mechanism by which HMGB1 becomes glycosylated despite
being devoid of signal peptide is still is unknown, as N-
glycosylation rarely exists in the cytosol. Based on a molecular
mass shift upon PNGase F treatment, as analyzed by western blot
and profiling of N-glycans, some amount of glycosylation is
linked to HMGB1.
The secretion of protein devoid of signal peptide is not fully
understood as the protein is unable to access the conventional
secretion pathway through the ER. IL-1β is a model protein
without a signal peptide and with an unconventional secretion
pathway based on the autophagy mechanism, an important
pathway for extracellular delivery (Dupont et al., 2011).
Autophagy has recently been shown to regulate selective
HMGB1 secretion in dying tumor cells (Thorburn et al.l,
2009). An investigation of the interaction of autophagy-based
unconventional secretion of HMGB1 and HMGB1 glycosylation
is needed to further identify and understand the pathophysiologic
mechanism of HMGB1-mediated inflammation. In summary,
HMGB1 can be N-glycosylated at N37 and either at residue
N134 or N135, and this determines the nucleocytoplasmic
transport, extracellular secretion and protein stability of
HMGB1.
Fig. 7. Stability of glycosylated HMGB1. (A) HEK293T cells were transfected with HMGB1WT, HMGB1N37Q/N134Q and HMGB1N37Q/N135Q plasmids and then
treated with 70 µg/ml cycloheximide (CHX) to observe protein degradation. HMGB1 levels were analyzed by western blotting to determine the protein degradation
rate. The experiment was repeated four times. Results are mean±s.e.m. *P<0.01, **P<0.001 (Student’s t-test). (B) HEK293T cells were transfected with each
HMGB1 plasmid for 24 h, and then treated with 10 μM MG132 in the presence or absence of 20 mM NH4Cl. Cell lysates were immunoblotted with anti-HMGB1
antibody, and the relative intensity of HMGB1 compared to GAPDH was measured. The experiment was repeated three times. Results are mean±s.e.m.
**P<0.001 (Student’s t-test). (C) HEK293T cells were co-transfected with Myc-tagged HMGB1 and HA–ubiquitin (Ub) plasmids and immunoprecipitated (IP) with
anti-Myc antibody. Immunoblot (IB) analyses were performed to observe HMGB1 ubiquitylation at K48, which signals degradation.
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MATERIALS AND METHODS
Cell culture, transfection and reagents
Human embryonic kidney (HEK) 293T, Chinese hamster ovary (CHO)-K1
cells and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS, Life
Technologies), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM
L-glutamine at 37°C under 5% CO2. Mouse macrophage cell lines J774A.1
and RAW264.7 were cultured in RPMI1640medium supplemented with the
reagents described above. Plasmid transfection was carried out using
Fugene HD reagent (Promega) as recommended by the manufacturer.
HEK293T cells were treated for 18 h with 15 ng/ml histone deacetylase
inhibitor trichostatin A (TSA, Sigma-Aldrich), 250 nM phorbol 12-
myristate 13-acetate (PMA, Sigma-Aldrich) and 20 μM H2O2 (Sigma-
Aldrich), to induce acetylation, phosphorylation and oxidation, respectively.
Proteasome inhibitor MG132 (0.5 μM, Sigma-Aldrich) and protein
biosynthesis inhibitor cycloheximide (CHX) (70 μg/ml, Sigma-Aldrich),
were also used. J774A.1 cells were treated with 100 ng/ml LPS (E. coli
0111:B4, Sigma-Aldrich) for HMGB1 secretion. Tunicamycin (10 µg/ml,
Sigma-Aldrich) was used for inhibition of N-glycosylation in HeLa,
RAW264.7 and CHO-K1 cells.
Plasmids and in situmutagenesis
Myc- and enhanced green fluorescent protein (EGFP)-tagged HMGB1WT
and HMGB1 glycosylation mutant genes were inserted into the pCMV
plasmid for mammalian cell expression. Site-directed mutations of
HMGB1 were generated utilizing pFastBac HT-B-HMGB1 as a template
using the QuikChange site-directed mutagenesis kit (Stratagene). Three
asparagine residues, N37, N134 and N135 were single or doubly mutated
to glutamine: HMGB1 N37Q, N134Q, N135Q, N37Q/N134Q, or
N37Q/N135Q. The sequences of primers used for construction of
human HMGB1 mutants are as follows: HMGB1 N37Q, 5′-CAGATGC-
TTCAGTCAATTCTCAGAGTTTTC-3′ (forward) and 5′-GAAAACTCT-
GAGAATTGGACTGAAGCATCTG-3′ (reverse); HMGB1 N134Q,
5′-AGAGATGTGGCAAAACACTGCTGCA-3′ (forward) and 5′-TGCA-
GCAGTGTTTTGCCACATCTCT-3′ (reverse); and HMGB1 N135Q, 5′-
AGATGTGGAATCAAACTGCTGCAGATG-3′ (forward) and 5′-CATC-
TGCAGCAGTTTGATTCCACATCT-3′ (reverse).
Recombinant HMGB1 cloning, expression and purification
An EcoRI–XhoI fragment containing full-length HMGB1WT and
HMGB1N37Q/N134Q (insHMGB1WT and insHMGB1N37Q/N134Q) were
cloned into pFastBac HT-B, and recombinant baculovirus was produced
according to the manufacturer’s manual (Invitrogen). The N-terminus six
histidine (6× His)-containing HMGB1 WT and N37Q/N134Q plasmids
were expressed by SF9 cells for 36 h. The insect cells were then purified on
a Ni-NTA column (GE Healthcare) with lysis buffer (25 mM Tris-HCl
pH 7.5, 300 mM NaCl, 10% glycerol, 30 mM imidazole, 5 mM
β-mercaptoethanol). HMGB1 was then eluted with elution buffer (25 mM
Tris-HCl pH 7.5, 300 mM NaCl, 10% glycerol, 300 mM imidazole,
5 mM β-mercaptoethanol). After tobacco etch virus (TEV) protease
treatment for 16 h at 4°C, size exclusion chromatography (Superdex-200
column, GE Healthcare) was carried out under buffer containing 25 mM
Tris-HCl pH 7.5 and 150 mM NaCl to verify protein homogeneity.
Western blot analysis and immunoprecipitation
HEK293T cells in six-well plates were transfected with various
combinations of plasmids using Fugene HD. For immunoblotting, cells
were washed with phosphate-buffered saline (PBS) and lysed in 1×
radioimmunoprecipitation assay (RIPA) buffer (GenDEPOT) containing
150 mM NaCl, 1% Triton X-100, 1% deoxycholic acid sodium salt, 0.1%
sodium dodecyl sulfate (SDS), 50 mM Tris-HCl pH 7.5, 2 mM EDTA and
protease inhibitor cocktail. Whole-cell lysates were centrifuged at 20,000 g
for 10 min at 4°C. Protein sample buffer was added to the whole-cell lysates
(100 mM Tris-HCl pH 6.8, 2% SDS, 25% glycerol, 0.1% bromophenol
blue, and 5% β-mercaptoethanol) followed by heating at 94°C for 5 min. In
all experiments, 20 μg protein were separated by molecular mass through
SDS-PAGE and transferred onto nitrocellulose membranes (GE
Healthcare). Non-specific binding sites were blocked by incubating the
membranes in Tris-buffered saline (TBS) supplemented with 0.1% Tween
20 and 5% (w/v) low-fat milk for 1 h. Anti-HMGB1 (Abcam; ab18256,
rabbit antibody against the region from amino acid 150 to the C-terminus of
HMGB1), anti-CRM1 and anti-HA (Santa Cruz Biotechnology), anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, AbFrontier), anti-
ubiquitin-K63 and -K48 (Millipore), and anti-c-Myc (Invitrogen
Technology) antibodies were used. Membranes were washed three times
for 10 min each with TBS with 0.1% Tween 20 (TBST), probed with the
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody
for 1 h, and washed three times for 10 min each with TBST. Enhanced
chemiluminescent (ECL) substrate (GenDEPOT) was then used for
visualization. Membranes were then stripped by submerging in stripping
buffer (50 mM glycine, pH 2.2) at room temperature for 1 h under constant
shaking.
Immunoprecipitation was performed with 200 μg protein, which was
pre-cleared with 20 μl of protein G beads (Sigma-Aldrich) for 1 h at 4°C,
followed by overnight incubation with 1 µg of the specific antibody. The
next day, samples were added to 20 μl of protein G beads and rotated at 4°C
for 2 h. The beads were then washed three times with ice-cold PBS, and then
mixed with protein sample buffer followed by heating at 94°C for 5 min.
The proteins were separated using SDS-PAGE.
A deglycosidase assay was performed to determine HMGB1 de-
glycosylation. Recombinant HMGB1 proteins HMGB1sig-pep and
insHMGB1WT were resuspended in 20 mM ammonium bicarbonate
buffer (pH 8.0) and boiled for 10 min at 98°C. HMGB1sig-pep (A&RT)
was produced in HEK293F cells by adding an ER-targeting Ig signal
peptide to HMGB1 (Leahy et al., 1988). The proteins were then treated with
PNGase F and incubated overnight at 37°C. Proteins were separated using
SDS-PAGE for western blotting.
RAW264.7 cells (1×106 cells/well) were treated with 1 µg/ml of LPS in
the presence of 10 µg/ml of brefeldin A and 10 µM nocodazole (Sigma-
Adrich) for 24 h to see whether HMGB1 was secreted by the conventional
secretion pathway. Culture supernatants and whole-cell lysates were
harvested, and HMGB1 was immunoblotted for HMGB1 secretion.
LC-MS/MS for peptide analysis
HMGB1 protein was purified from HEK293T cells transfected with a Myc–
HMGB1 plasmid for 48 h. Cells were lysed with 1× RIPA buffer and then
protein G beads conjugated with anti-Myc antibody were added to the
lysates. Beads were rotated at 4°C overnight and then washed three times
with ice-cold PBS. Samples were mixed with protein sample buffer, boiled
at 94°C for 5 min, and then separated using SDS-PAGE followed by
Coomassie Blue staining. The HMGB1 band was extracted from the gel for
analysis. Endogenous HMGB1 protein was prepared from whole-cell lysate
of HEK293T cells to detect the presence of N-glycosylated residues in
naturally expressed HMGB1. Whole-cell lysate was immunoprecipitated
with anti-HMGB1 antibody conjugated to protein G beads, which were pre-
cleared.
HMGB1 proteins were treated with PNGase F for LC-MS/MS analysis.
LC-MS/MS analysis was performed with a nano high performance liquid
chromatography (HPLC) system (Agilent) using the nano chip column
(150 mm×0.075 mm) for peptide separation. Mobile phase A for liquid
chromatography separation was 0.1% formic acid in deionized water and
mobile phase B was 0.1% formic acid in acetonitrile. The chromatography
gradient was designed for a linear increase from 5% B to 30% B in 25 min,
40% B to 60% B in 5 min, 90% B in 10 min, and 5% B in 15 min. The flow
rate was maintained at 300 nl/min. Product ion spectra were collected in the
information-dependent acquisition (IDA) mode and were analyzed by
Agilent 6530 Accurate-Mass quadrupole time-of-flight (Q-TOF) using
continuous cycles of one full scan TOF mass spectrometry reading from
200–1500 m/z (1.0 s) plus three product ion scans from 50–1800 m/z (1.5 s
each). Precursor m/z values were selected starting with the most intense ion
and using a selection quadrupole resolution of 3 Da. The rolling collision
energy feature was used, which determines collision energy based on the
precursor value and charge state. The dynamic exclusion time for precursor
ion m/z values was 60 s. The mascot algorithm (Matrixscience) was used to
identify peptide sequences present in a protein sequence database. Mascot
searches against an in-house database of HMGB1 (Genbank accession no.
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CAG33144.1) were performed with the following criteria: fixed
modification, carboxyamidomethylated at cysteine residues, variable
modification, oxidized at methionine residues, deamidation at aspartic
acid and asparagine, maximum allowed missed cleavage of 2, mass
spectrometry tolerance of 100 ppm, and MS/MS tolerance of 0.1 Da. Only
peptides resulting from trypsin digests were considered.
Profiling of HMGB1 N-glycans
For the HMGB1 N-glycan analysis, HEK293T cells were transfected with
myc–HMGB1 plasmid for transient expression. Whole-cell lysate was
prepared and the protein supernatant was applied to the affinity column of a
c-Myc tag immunoprecipitation or co-immunoprecipitation kit (Pierce). The
purity of myc–HMGB1 was confirmed to be sufficient by analyzing for N-
glycans. A total of 15 μg of myc–HMGB1 protein was treated with PNGase
F and then labeled with RapiFlour reagent (Waters). The final solution was
diluted with acetonitrile for HILIC enrichment. The glycan enrichment was
performed with a Waters GlycoWorks™ HIULIV µElution Plate, based on
the manufacturer’s protocol. Briefly, the well was washed with 200 µl of
deionized water and primed with 200 µl of 85% acetonitrile. Then, the
labeled glycan sample was loaded to the well and washed with 2×600 µl of
1:9:90 (v/v/v) formic acid:water:acetonitrile solution. Finally, the glycans
were eluted with 3×30 µl of 200 mM ammonium acetate in 5% acetonitrile.
The enriched glycan was injected onto the ACQUITY I UPLC Glycan BEH
amide column (2.1 mm×150 mm, 1.7 µm particle size, Waters). Separation
was performed with eluent A, consisting of 50 mM ammonium formate, and
eluent B, consisting of 100% acetonitrile, with a 35-min liner gradient from
25% to 46% eluent A at a flow rate of 0.4 ml/min. The effluent was electro-
sprayed into the LTQ Elite (Thermo). Blanks were run prior to the sample
run to ensure that there were no significant signals from the solvents or the
column. A database search was carried out using a SimGlycan algorithm
(SimGlycan v5.0).
Confocal microscopy
In order to observe nuclear–cytoplasmic translocation of HMGB1 in
HEK293T cells under various stimulation conditions, HEK293T cells were
transfected with EGFP-tagged HMGB1WT and mutant plasmids and
cultured on cover glass in a six-well plate. After 48 h, cells were treated
with 50 μM H2O2 for 2 h, 250 µM PMA for 4 h and 10 ng/ml TSA for 2 h.
Cells were fixed with 4% paraformaldehyde-PHEM buffer (60 mM
PIPES, 25 mM HEPES, 10 mM EGTA and 4 mM MgSO4, pH 7.0) for
20 min at room temperature and washed with cold PBS. After mounting
with 4′,6′-diamidino-2-phenylindole (DAPI), cells were observed with a
confocal FV1000 microscope (Olympus).
Nuclear and cytosolic fractionation
Nuclear and cytosolic fractionation was performed using a nuclear and
cytosolic fractionation kit (BioVision). HEK293T cells in six-well plates
were transfected with HMGB1 WT, N37Q/N134Q or N37Q/N135Q
plasmids and incubated for 48 h. Cells were incubated with Earle’s
balanced salt solution (EBSS) for 4 h to induce starvation and then harvested
by centrifugation at 600 g for 5 min at 4°C. Samples were added to 0.2 ml
cytosol extraction buffer (CEB)-A containing dithiothreitol (DTT) and
protease inhibitors. Samples were vigorously vortexed for 15 s to fully
resuspend the cell pellet, and then incubated on ice for 10 min followed by
addition of 11 μl of ice-cold CEB-B. Samples were vortexed for 5 s,
incubated on ice for 10 min and then centrifuged for 5 min at 16,000 g. The
supernatant fraction (cytoplasmic extraction) was then transferred to a clean
pre-chilled tube. The pellets containing the nuclei were resuspended in
100 μl of ice-cold nuclear extraction buffer (NEB) mixture, vortexed for
15 s, returned to ice and vortexed for 10 min, and then centrifuged at 16,000
g for 10 min. The supernatant (nuclear extract) was immediately transferred
to a clean pre-chilled tube.
Gel mobility shift assay
In order to observe the DNA binding of wild-type and mutant HMGB1
proteins, a gel retardation assay was performed. Plasmid DNAwas prepared
by EcoRI digestion and then purified. Recombinant HMGB1WT and
HMGB1N37Q/N134Q were then incubated with plasmid DNA at 37°C for 2 h
and migration was analyzed on a 1% agarose gel.
FRAP
A FRAP assay was performed to analyze the binding of HMGB1 to nuclear
DNA within the nucleus by measuring the mobility of HMGB1. HEK293T
cells were seeded on covered glass-bottom dishes and transfected with GFP-
tagged HMGB1 WT, N37Q/N134Q or N37Q/N135Q plasmids for 48 h.
Transfected cells were viewed under a confocal FV1000 fluorescent
microscope and bleached using laser diode at 405 nm at 90% for 3 s. The
nuclei were then scanned to measure the recovery rate of GFP fluorescence by
region optical intensity (ROI) value. FRAPgraphswere created usingLiveplot.
Modeling of N-glycosylated HMGB1 structure in silico
In order to draw a model of the N-glycosylated HMGB1 structure, we used
the complex structures of HMGB1 A box and B box bound to dsDNA as
templates (PDB ID 1CKT and 2GZK, respectively). Two N-acetyl-D-
glucosamine (GlcNAc) molecules, which are the first two sugars of
glycosylation, were manually attached to HMGB1 N37 and N134 using
the WinCoot program (Emsley and Cowtan, 2004). The cartoon or stick
structures were produced by the PyMOL program (PyMOL, http://www.
pymol.org).
Statistical analysis
Analysis of experiments was performed with Student’s t-test using
GraphPad Prism. Data represent the mean±s.e.m., as indicated in the
individual figure legends. The difference was considered statistically
significant when P<0.05.
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